Literature DB >> 18093677

Functional modification of Sendai virus by siRNA.

Kotaro Saga1, Katsuto Tamai, Masako Kawachi, Takashi Shimbo, Hiroshi Fujita, Takehiko Yamazaki, Yasufumi Kaneda.   

Abstract

Sendai virus (hemagglutinating virus of Japan; HVJ) is a negative-strand RNA virus with robust fusion activity, and has been utilized for gene transfer and drug delivery. Hemagglutinin-neuraminidase (HN) protein on the viral membrane is important for cell fusion, but causes agglutination of red blood cells. HN-depleted HVJ has been desired for in vivo transfection in order to improve safety. Here, we succeeded in producing HN-depleted HVJ using HN-specific short interfering RNA (siRNA). Viral production was not affected by the siRNA. HN protein was markedly decreased in the new HVJ, while other viral proteins were retained. Consequently, the hemagglutinating activity was substantially reduced and infection activity was suppressed. When the HN-depleted HVJ was mixed with cultured cells and the mixture was centrifuged for 10min at 2000xg, the modified HVJ recovered its infectivity to approximately 80% of wild HVJ. However, infectivity was abolished in the presence of anti-F antibody. Moreover, transfection of FITC-labeled oligodeoxynucleotides using the modified HVJ was also recovered by centrifugation. Thus, the HN-depleted HVJ produced using siRNA technology will be applicable to a delivery vector.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18093677     DOI: 10.1016/j.jbiotec.2007.10.003

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  4 in total

1.  Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo.

Authors:  Hitoshi Fujii; Akifumi Matsuyama; Hiroshi Komoda; Masao Sasai; Minoru Suzuki; Tomoyuki Asano; Yuichiro Doki; Mitsunori Kirihata; Koji Ono; Yasuhiko Tabata; Yasufumi Kaneda; Yoshiki Sawa; Chun Man Lee
Journal:  Radiat Oncol       Date:  2011-01-20       Impact factor: 3.481

Review 2.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411

Review 3.  Oncolytic Sendai virus-based virotherapy for cancer: recent advances.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Oncolytic Virother       Date:  2015-10-01

4.  Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene.

Authors:  Yingzhe Jiang; Kotaro Saga; Yasuhide Miyamoto; Yasufumi Kaneda
Journal:  Oncotarget       Date:  2016-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.